The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | The real-world experience of Dara-VTd in transplant-eligible multiple myeloma
Salam Youssef, Guy’s and St Thomas’ NHS Foundation Trust, London, UK, discusses the real-world use of daratumumab, bortezomib, thalidomide, and dexamethasone (Dara-VTd) in transplant-eligible patients with multiple myeloma (MM). Treatment consists of four cycles of Dara-VTd for induction therapy, followed by autologous stem cell transplantation (autoSCT), 2 cycles of consolidation, and subsequent lenalidomide maintenance. The majority of patients achieved a very good response or better. Audit data indicate adequate monitoring of patients throughout Dara-VTd treatment. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Menarini stemline, Janssen; Conference attendance/ travel expenses: Gilead, Beigene, Pfizer.
